Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: A meta-analysis
Although there have been recent advances in irradiation techniques and the use of concurrent chemo-radiotherapy, local recurrence still remains a major cause of therapeutic failure in patients with nasopharyngeal carcinoma (NPC), with a rate of approximately 8 –10% [1,2]. It is still a challenge in clinical practice to implement effective treatment for patients with locally recurrent NPC (r-NPC) who had received a previous full-dose of radiation therapy (RT), especially in patients with advanced T stage and/ or a bulky tumor volume [3]. (Source: Oral Oncology)
Source: Oral Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Qiuyuan Yue, Mingwei Zhang, Yunbin Chen, Dechun Zheng, Ying Chen, Meimei Feng Tags: Review Source Type: research
Surgical outreach and microvascular surgery in developing countries
Global Health collaborations between resource-poor and resource-rich health systems can have bidirectional benefits [1]. For the resource-rich participants, medical outreach can fulfill personal philanthropic goals and provide a service that may be otherwise unattainable by the recipients. It may also allow them to fulfill academic goals such as training domestic and international learners, developing relationships for research collaborations, and creating programs and infrastructure abroad. From an academic, service and infrastructure point of view, the resource-limited participants also benefit from these services. (Source: Oral Oncology)
Source: Oral Oncology - April 30, 2018 Category: Cancer & Oncology Authors: Chad A. Zender, Kate Clancy, Jason E. Thuener, Kyle Mannion Source Type: research
Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy
Nasopharyngeal Carcinoma (NPC) is an epithelial carcinoma of the nasopharynx, invariably associated with the Epstein Barr Virus (EBV) [1]. Worldwide, there are approximately 86,000 incident cases annually [2]. It is an uncommon cancer in the United States with an incidence of 0.5 –2 per 100,000 compared with 25 per 100,000 in southern China [3]. In the United States, the most common histology, seen in approximately two-thirds of patients, is undifferentiated, non-keratinizing (World Health Organization Type III); in China, this type accounts for 95% of all nasopharyngeal c ancers [4]. (Source: Oral Oncology)
Source: Oral Oncology - April 30, 2018 Category: Cancer & Oncology Authors: Frank E. Mott, Renatta Ferrarotto, Theresa Nguyen, Jack Phan Source Type: research
Editorial Board/Aims & Scope
(Source: Oral Oncology)
Source: Oral Oncology - April 27, 2018 Category: Cancer & Oncology Source Type: research
Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy
Immune check point inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum failure [1]. In many tumors, anti PD1 or anti PDL 1 have increased median overall survival (OS) but have not demonstrated greater median progression free survival (PFS) [1 –3]. Recent data has suggested that chemotherapy in post-nivolumab treatment may induce better objective responses than historical data did [4]. (Source: Oral Oncology)
Source: Oral Oncology - April 24, 2018 Category: Cancer & Oncology Authors: Amaury Daste, Erwan De-Mones, Val érie Cochin, Charles Dupin, Laurence Digue, Alain Ravaud, Charlotte Domblides Tags: Letter to the editor Source Type: research
Assessing the carcinogenic potential of E-cigarette
Past decade has seen a significant rise in the use of E-cigarette especially among youngsters. The increasing popularity of E-cigarette is largely due to its marketing as a safe alternative to conventional smoking. Recent studies have shown that the health hazards posed by e-cigarette are comparable to that of conventional smoking. Studies have also shown the presence of several potential carcinogens including tobacco-specific nitrosamines, carbonyls (formaldehyde, acetaldehyde) in e-cigarettes [1]. (Source: Oral Oncology)
Source: Oral Oncology - April 23, 2018 Category: Cancer & Oncology Authors: A. Thirumal Raj, Shankargouda Patil, Kamran Habib Awan, Shivaranjhany Sivakumar Tags: Letter to the editor Source Type: research
Immune cell infiltration in Ectomesenchymal chondromyxoid tumor: An immunohistochemical study
This report describes, for the first time, the morphological and immunohistochemical features of a unique ECT case, which revealed diffuse infiltration by immune cells with a dendritic-like appearance inside the tumor proliferation. The significance of these findings and discussion about the tumor cell-immune cell interactions are presented. (Source: Oral Oncology)
Source: Oral Oncology - April 20, 2018 Category: Cancer & Oncology Authors: Luciana Yamamoto Almeida, Matheus Henrique Lopes Dominguete, Paulo Roberto Dominguete, Alfredo Ribeiro-Silva, Lucas Ribeiro Teixeira, Jorge Esquiche Le ón Tags: Letter to the editor Source Type: research
Age- and localization-dependent functional and psychosocial impairments and health related quality of life six months after OSCC therapy
The incidence of oropharyngeal tumors of the oral cavity (ICD-10) in Germany has been on the rise since 2009, with 66,814 reported cases between 2009 and 2013 [1]. Approximately 59.6% of these patients were older than 60 years [1]. The absolute number of new cancer cases has almost doubled since the early 1970s [1]. One important cause, but not the only one for this increase is the demographic aging of the population during this period [1]. The oral squamous cell carcinoma (OSCC) is the most common cancer of the oral cavity [2]. (Source: Oral Oncology)
Source: Oral Oncology - April 18, 2018 Category: Cancer & Oncology Authors: Sabine S. Linsen, Nils-Claudius Gellrich, Gertrud Kr üskemper Source Type: research
Nivolumab vs investigator ’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Squamous cell carcinoma of the head and neck (SCCHN) includes neoplasms in the oral cavity, pharynx, and larynx, and accounts for 90% of all head and neck cancers [1 –3]. Patients with recurrent/metastatic (R/M) SCCHN who progress within 6 months after platinum-based therapy have poor long-term prognosis and limited treatment options, with a median overall survival (OS) of ≤6 months [4,5]. In 2016, nivolumab was approved in the United States for the trea tment of this patient population, with European approval following in 2017 [6,7]. (Source: Oral Oncology)
Source: Oral Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Robert L. Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Source Type: research
A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients
Various treatment approaches are available for patients with non-metastatic head and neck squamous cell carcinoma (HNSCC) including radiation as monotherapy or in combination with systemic therapy and/or surgery. Currently, several trials testing treatment de-intensification in low risk patients are in progress [1] and a few phase I trials testing treatment intensification in patients with assumed high risk of recurrence has been conducted [2 –4]. In both cases, it is important to select the appropriate study population for each trial. (Source: Oral Oncology)
Source: Oral Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Jacob H. Rasmussen, Katrin H åkansson, Gregers B. Rasmussen, Ivan R. Vogelius, Jeppe Friborg, Barbara M. Fischer, Søren M. Bentzen, Lena Specht Source Type: research
Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer
Definitive (chemo)radiotherapy (CRT) is a curative treatment option for inoperable, locally advanced oral squamous cell carcinoma (OSCC) [1]. However, it appears that definitive CRT in OSCC does not achieve similarly high locoregional control or disease specific survival rates as in laryngeal and pharyngeal squamous cell carcinoma (L/P-SCC) [2,3]. Current HNSCC treatment guidelines reflect this and L/P-SCC is preferably treated with definitive CRT and OSCC with surgery followed by postoperative radiotherapy with or without chemotherapy (S-PORT). (Source: Oral Oncology)
Source: Oral Oncology - April 13, 2018 Category: Cancer & Oncology Authors: David M. Vossen, Caroline V.M. Verhagen, Marcel Verheij, Lodewyk F.A. Wessels, Conchita Vens, Michiel W.M. van den Brekel Source Type: research
Multi-modality 3D mandibular resection planning in head and neck cancer using CT and MRI data fusion: A clinical series
Surgical removal of squamous cell carcinomas in the oral cavity close to mandibular bone, often necessitates a resection of the mandible. A microscopic free margin of at least 5 mm on both sides of the resection is required according to clinical guidelines [1]. The oncologic-surgical challenge is to perform an adequate resection with sufficient margin, based on the pre-operative information. (Source: Oral Oncology)
Source: Oral Oncology - April 11, 2018 Category: Cancer & Oncology Authors: J. Kraeima, B. Dorgelo, H.A. Gulbitti, R.J.H.M. Steenbakkers, K.P. Schepman, J.L.N. Roodenburg, F.K.L. Spijkervet, R.H. Schepers, M.J.H. Witjes Source Type: research
